D3 Bio presents first-line data for elisrasib in untreated NSCLC

Key facts

• D3 Bio presented first-line data for elisrasib at ASCO 2026.
• Elisrasib monotherapy showed a 78.0% ORR and 12.4 months median PFS in first-line KRAS G12C-mutant NSCLC.
• The combination of elisrasib with pembrolizumab achieved an 81.3% ORR in first-line KRAS G12C-mutant NSCLC.
• Data presented is preliminary with a manageable safety profile.

D3 Bio presented data for its drug elisrasib (D3S-001) at ASCO 2026. Elisrasib is a next-generation KRAS G12C inhibitor. The data focused on its efficacy in the first-line treatment of non-small cell lung cancer (NSCLC) with KRAS G12C mutations.